GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease
Read more at globenewswire.comGenocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here